About US
Contact us
-
Hong Kong's cheaper prices for Sovaldi, Herceptin and other drugs draw throngsGilead Sciences' ($GILD) hep C drugSovaldiis not yet available on mainland China, at least not legitimately. But it is in Hong Kong, and buyers who ask quietly at small pharmacies along Nathan Road ca2015/10/12
-
Sun kills lawsuit Ranbaxy filed against FDA for pulling its Nexium genericWhen the FDA last year yanked away its initial approval of Ranbaxy's generics of two blockbusters including the heartburn med Nexium, the Indian drugmaker fired back with a lawsuit against the FDA. Bu2015/10/10
-
U.K. cost watchdog gives second thumbs-up in a week to Merck's Keytruda for skin cancerMerck's ($MRK) Keytruda is two-for-two this week with the U.K.'s cost watchdog, nabbing a thumbs-up as a first-line treatment for skin cancer days after the National Institute of Health and Care Excel2015/10/10
-
Advera Health Analytics: Novartis, Allergan Alzheimer's meds linked to abnormal behavior, blood pressure side effectsAlzheimer's drug development is a difficult venture, as pharma knows all too well. The meds' troubling side effects and potential safety issues make marketing a risky game, with few companies grabbing2015/10/10
-
Biogen, Sanofi, Novartis tout long-term benefits at ECTRIMS as new competition advancesBiogen, Sanofi ($SNY) and Novartis ($NVS) are all trumpeting new data showing long-term benefits for their respective meds at this year's European Committee for Treatment and Research in Multiple Scle2015/10/9
-
Sources: Sanofi tells unions a 25% gain at French production sites is neededVery public run-ins between ex-Sanofi CEOChris Viehbacherand France's powerful unions were one factor that reportedly cost him his job. Now his replacement,Olivier Brandicourt, will see if he can do a2015/10/9
-
Merck notches another win in India patent battle over diabetes bestsellersEverything is coming up roses for Merck ($MRK) in its patent battle withIndia'sGlenmark Pharmaceuticalsover copycats of the drugmaker's diabetes medsJanuviaandJanumet, as the Delhi High Court barred t2015/10/8
-
Sanofi offers some data that might help Aubagio as it chases market shareSanofi'smultiple sclerosispillAubagiohas been an also-ran behind established drugs like Teva's ($TEVA)Copaxoneand newer drugs like Biogen's ($BIIB)Tecfidera. But the French drugmaker has not given up2015/10/8
-
Pfizer CEO sees no real future for Clinton's drug-pricing proposalsPfizer ($PFE) CEOIan Readisn't too worried about proposals to crack down on U.S. drug pricing. Presidential candidateHillary Clinton's slate of new measures--which include negotiating power for Medica2015/9/30
-
Who's most at risk if the U.S. cracks down on prices? Gilead, Celgene top the listWith pharma's U.S. pricing power apparently in jeopardy, industry watchers are worried. Just take a look at drug stocks' performance over the past week or so, as a firestorm over an enormous price inc2015/9/30